Regenerex Pharma (RGPX) Non Operating Income (2019 - 2025)

Regenerex Pharma (RGPX) has 7 years of Non Operating Income data on file, last reported at -$27302.0 in Q3 2025.

• Non Operating Income for Q3 2025 came in at -$27302.0, up 89.93% year-over-year; the trailing twelve-month figure through Sep 2025 was -$468580.0 (down 43.5% YoY), and the FY2025 annual result was -$700944.0, down 798.62% from the prior year.
• Non Operating Income rose to -$27302.0 in Q3 2025 per RGPX's latest filing, from -$29801.0 in the prior quarter.
• Over five years, Non Operating Income peaked at $3068.0 in Q3 2022 and troughed at -$408461.0 in Q1 2025.
• A 5-year average of -$52279.1 and a median of -$18145.5 in 2023 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2021 and 2022: Non Operating Income plunged 6061.05% in 2021, then jumped 130.02% in 2022.
• A 5-year view of Non Operating Income shows it stood at -$16437.0 in 2021, then fell by 23.49% to -$20298.0 in 2022, then dropped by 21.15% to -$24592.0 in 2023, then jumped by 87.74% to -$3016.0 in 2024, then slumped by 805.24% to -$27302.0 in 2025.
• Business Quant data shows RGPX's Non Operating Income at -$27302.0 in Q3 2025, -$29801.0 in Q2 2025, and -$408461.0 in Q1 2025.